We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Andrx has relinquished its 180-day exclusive marketing rights for a 150-mg strength version of GlaxoSmithKline’s (GSK’s) smoking cessation drug Zyban (bupropion HCl), a move that allows generic firms to start marketing the drug.